Histone deacetylase (HDAC) plays important role in the regulation of several cellular properties intimately interlinked with the development of cancer. Histone deacetylase inhibitors have been developed clinically for malignant tumors due to their effect on apoptosis. Belinostat is a histone deacetylase inhibitor with anticancer activity used for the treatment of peripheral T-cell limphoma malignancies. In this study, based on the structure of belinostat, two novel derivatives have been successfully synthesized with a simple, efficient synthesis process using conventional organic reactions suitable for laboratories in Viet Nam. The structure of these two derivatives was fully confirmed by spectroscopic analytical methods such as MS and 1H-NMR, and assessed for its ability to inhibit histone deacetylase by in silico method.